Top Story

Sunitinib active in meningioma

August 29, 2014

Sunitinib demonstrated encouraging activity in patients with recurrent and progressive meningioma, according to results of a prospective, multicenter, single-arm phase 2 study.

The analysis included 36 patients with atypical (n=30) or anaplastic (n=6) meningioma.

FDA News

FDA grants orphan drug status to cannabidiol for glioblastoma multiforme

August 26, 2014
Insys Therapeutics recently announced that the FDA has granted orphan drug designation to a pharmaceutical cannabidiol for the treatment of glioblastoma…
Case Challenges

A 54-year-old woman with bilateral hydronephrosis

HemOnc Today, August 25, 2014
Ramya Varadarajan, MD
A 54-year-old black woman presented to her primary care physician after experiencing worsening fatigue and abdominal pain for about 1 month.

Bevacizumab plus lomustine improved outcomes in recurrent glioblastoma

July 30, 2014
The combination of lomustine plus bevacizumab induced higher OS rates than either agent alone, according to results of a randomized, open-label phase 2 trial.Patients…
CME

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

8/16/2014
Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
CME

New Advances, New Options: Evaluating the Changing Landscape of Hemophilia to Optimize Patient Outcomes

This activity is supported by an educational grant from Biogen Idec.

8/16/2014
The bleeding abnormalities associated with hemophilia can have devastating consequences for patients. Recent advances…
More »

Filter By:

In the Journals

Sunitinib active in meningioma

August 29, 2014
Sunitinib demonstrated encouraging activity in patients with recurrent and progressive meningioma, according to results of a prospective…
FDA News

FDA grants orphan drug status to cannabidiol for glioblastoma multiforme

August 26, 2014
Insys Therapeutics recently announced that the FDA has granted orphan drug designation to a pharmaceutical cannabidiol for the treatment of…
Case Challenges

A 54-year-old woman with bilateral hydronephrosis

HemOnc Today, August 25, 2014
Ramya Varadarajan, MD
A 54-year-old black woman presented to her primary care physician after experiencing worsening fatigue and abdominal pain for about 1 month.

Bevacizumab plus lomustine improved outcomes in recurrent glioblastoma

July 30, 2014
The combination of lomustine plus bevacizumab induced higher OS rates than either agent alone, according to results of a randomized, open-label phase…
Institution Notes

Neuroblastoma Research Association presents lifetime achievement award

July 13, 2014
Garrett M. Brodeur, MD, a pediatric oncologist with the Cancer Center at The Children’s Hospital of Philadelphia, received the Advances in…
In the Journals

Risk assessment models predicted VTE risk in high-grade gliomas

July 11, 2014
Researchers used biomarkers to develop two risk assessment models that accurately identified patients with newly diagnosed high-grade gliomas who…
In the Journals

Recurrent VTE linked to certain cancers, leg paresis

July 9, 2014
Specific types of malignancies — including brain, lung and ovarian cancers, as well as myeloproliferative or myelodysplastic disorders —…
Industry News

Glioblastoma vaccine improved OS vs. standard care

July 2, 2014
The addition of heat shock protein-peptide complex-96 vaccine significantly extended OS compared with standard care alone among patients with newly…

Top 8 lessons learned at ASCO 2014

June 25, 2014
The theme of this year’s ASCO Annual Meeting, “Science and Society,” emphasized patient-centered focus — looking at the full…
FDA News

Investigational glioblastoma drug receives fast track designation from FDA

June 17, 2014
The FDA has granted fast track designation to DNAtrix Inc.’s replication competent adenovirus for patients with recurrent glioblastoma…
More Headlines »